Drug Profile
Cannabidivarin - GW Pharmaceuticals
Alternative Names: CBDV; CBDV - GW Pharmaceuticals; GWP-42006Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator GW Pharmaceuticals
- Developer Charite - Universitatsmedizin Berlin; GW Pharmaceuticals; Montefiore Medical Center
- Class Analgesics; Antiepileptic drugs; Behavioural disorder therapies; Cannabinoids; Small molecules
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Autistic disorder; Neuropathic pain; Partial epilepsies; Pervasive child development disorders; Prader-Willi syndrome; Rett syndrome
- No development reported Epilepsy
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for clinical-Phase-Unknown development in Epilepsy in USA
- 05 May 2021 GW Pharmaceuticals has been acquired by Jazz Pharmaceuticals plc
- 12 May 2020 Phase-II clinical trials in Prader-Willi syndrome (In children, In adolescents, In adults) in USA (unspecified route) (NCT03848481)